Advanced NSCLC patients have obtained great benefits from the progressive treatments available, including epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs),7 antiangiogenic agents,8 and immune checkpoint inhibitors.9 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.